Phase 4Recruiting

Glycemic Variability of Combination Therapies in T2DM

A Multicenter Study to Evaluate Efficacy and Safety

Sponsor
JW Pharmaceutical (Industry)
Enrollment
178 planned
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Empagliflozin/Metformin; Anagliptin; Metformin; Empagliflozin/Linagliptin
Ages
adults, older adults
Registry
NCT07442006

Full record on ClinicalTrials.gov

From the registry

Glycemic Variability of Combination Therapies in T2DM

Primary outcomes

  • Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12

History

  1. Primary completion expected

  2. Registered

  3. Started